BRIEF-Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)

Candel Therapeutics, Inc.

CADL

0.00

May 15 (Reuters) - Candel Therapeutics Inc CADL.O:

CANDEL THERAPEUTICS REPORTS EXTENDED CLINICAL BENEFIT OVER MULTIPLE CLINICAL ENDPOINTS IN PATIENTS FROM PHASE 3 TRIAL OF AGLATIMAGENE BESADENOVEC (CAN-2409) IN LOCALIZED PROSTATE CANCER UNDER PROLONGED FOLLOW-UP AT AUA 2026 ANNUAL MEETING

Source text: ID:nGNX89XTBc

Further company coverage: CADL.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.